Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 22,541 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Cancer
Interventions
FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
19
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Conditions
Gastrointestinal Stromal Tumors
Interventions
Nilotinib, Best Supportive Care (BSC) +/- imatinib or sunitinib
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
Conditions
Wellness, Health
Interventions
Ubiquinol + geranylgeraniol, Geranylgeraniol, Ubiquinol, Ubiquinone, Placebo
Dietary Supplement · Other
Lead sponsor
OvationLab
Network
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
6
States / cities
El Dorado Hills, California • Centennial, Colorado • Palm Springs, Florida + 3 more
Active, not recruiting Phase 1Phase 2 Interventional

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational

Twelve Month Follow-Up of CP0108

NCT02209012
Conditions
Actinic Keratosis
Interventions
Aminolevulinic Acid (ALA), Topical Solution Vehicle, BLU-U Blue Light Photodynamic Therapy Illuminator
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 10 more
Conditions
Rheumatoid Arthritis
Interventions
AZD1163, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Glendale, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 25 more
Conditions
Epilepsies, Partial
Interventions
pregabalin 600 mg/day, pregabalin 150 mg/day
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
63
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
Conditions
Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative Disorders, Hematologic Diseases
Interventions
Campath, Busulfan, Fludarabine, Hematopoietic stem cell infusion, FK-506
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Houston, Texas
Conditions
Cirrhosis, Liver
Interventions
GI262570 0.5 mg, GI262570 1.0 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 45 more
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Medical Chart Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
NSCLC
Interventions
EP0031, Platinum chemotherapy, Pemetrexed
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 16 more
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
186
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 143 more
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 50 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
31
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more
Conditions
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
Interventions
Pirtobrutinib, Ibrutinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
737 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
19
States / cities
Anaheim, California • Cerritos, California • Palo Alto, California + 15 more
Conditions
Alcohol Associated Hepatitis
Interventions
INT-787, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • Sacramento, California + 17 more
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
79
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
42
States / cities
Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Conditions
Hodgkin Lymphoma
Interventions
brentuximab vedotin, doxorubicin, bleomycin, vinblastine, dacarbazine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
83
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
38
States / cities
Birmingham, Alabama • Beverly Hills, California • Burbank, California + 35 more
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, paclitaxel poliglumex
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
34
States / cities
Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 31 more
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Oral Contraception Under Simulated OTC Conditions

NCT03559010
Conditions
Contraception
Interventions
Norgestrel 0.075 mg tablets
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
12 Years and older · Female only
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
44
States / cities
Birmingham, Alabama • Homewood, Alabama • McCalla, Alabama + 38 more
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
Interventions
CG-806
Drug
Lead sponsor
Aptose Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
30
States / cities
Los Angeles, California • Monterey, California • Redondo Beach, California + 25 more
Conditions
Non-Constipation Irritable Bowel Syndrome
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Hueytown, Alabama • Phoenix, Arizona • Sierra Vista, Arizona + 78 more